Cabozantinib for adults with previously treated neuroendocrine tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will follow about 150 adults with unresectable or metastatic, well-differentiated pancreatic or extra‑pancreatic neuroendocrine tumors who are starting cabozantinib as part of routine care. No extra procedures are required; investigators will collect data from standard medical visits, tests, and imaging to document tumor response, duration on treatment, side effects, and patient-reported quality of life. All participants must have received at least one prior systemic therapy (other than somatostatin analogues) and provide informed consent. The study is being conducted at regular hospitals and clinics in Germany and Austria to capture real-world use of cabozantinib.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Participants can join the study if they meet all of the following conditions:

* Are 18 years or older and able to give informed consent.
* Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
* Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
* Have already received at least one prior systemic therapy, other than somatostatin analogues.
* Have signed a written informed consent form.

Exclusion Criteria:

Participants cannot join the study if:

* They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
* They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.

Where it's running

• Medizinische Universitaet Graz
  Graz, Austria Recruiting
• Medizinische Universität Wien
  Vienna, Austria Recruiting
• MVZ am Klinikum Aschaffenburg
  Aschaffenburg, Germany Recruiting
• Charité - Universitaetsmedizin Berlin
  Berlin, Germany Recruiting
• DRK Kliniken Berlin
  Berlin, Germany Recruiting
• Evangelische Lungenklinik Berlin
  Berlin, Germany Recruiting

Study contacts

• Study coordinator: Ipsen Clinical Study Enquiries
• Email: clinical.trials@ipsen.com
• Phone: See e mail

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Alternative dosing schedule for cabozantinib in advanced kidney and neuroendocrine tumors

  This study is testing a new way to give cabozantinib to see if it helps people with advanced kidney cancer and neuroendocrine tumors feel better and stay safe while being treated.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT05263050

• Intensified monitoring to personalize cabozantinib dosing in advanced kidney cancer

  We will test whether closer pharmacology-based monitoring helps people with advanced kidney cancer tolerate cabozantinib better while keeping its effect against the cancer.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordenone · NCT07805122

• New DLL3 PET/CT imaging for neuroendocrine tumors compared with standard scans

  A new PET/CT scan using the 68Ga-DLL3 nanobody is being tested to see if it detects metastatic neuroendocrine tumors better than current scans in adults.

  Recruiting at 2 sites Phase 2 Peking University First Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07733024

• CTX-471 for NCAM-positive metastatic neuroendocrine tumors

  A phase 2 trial is testing CTX-471 in adults with NCAM (CD56) positive metastatic neuroendocrine tumors that have progressed after standard therapy.

  Recruiting at 2 sites Phase 2 Compass Therapeutics · St Louis, Missouri and 1 other locations · NCT07684170

• Terbium-161 DOTATATE for metastatic gastro‑enteropancreatic neuroendocrine tumors

  This trial tests terbium-161 DOTATATE, a targeted radioactive drug, in adults with metastatic well-differentiated GEP‑NETs who have progressed after lutetium‑177 therapy.

  Recruiting at 2 sites Phase 2 Tata Memorial Hospital · Mumbai, Maharashtra and 1 other locations · NCT07404176

• Sapu003 with or without exemestane for advanced mTOR-sensitive solid tumors

  This phase 1b test will try weekly IV Sapu003, given with exemestane for HR+/HER2- breast cancer or alone for other mTOR-sensitive advanced tumors, to see if it's safe and how your body handles it.

  Recruiting Phase 1 Sapu Nano (Us) LLC · Adelaide · NCT07369505

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.